3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors
    4.
    发明申请
    3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors 审中-公开
    作为细胞周期蛋白依赖性激酶(Cdk)或极光激酶或糖原合酶3(Gsk-3)抑制剂的3,4-二取代吡唑类

    公开(公告)号:US20080004270A1

    公开(公告)日:2008-01-03

    申请号:US11571713

    申请日:2005-07-05

    摘要: The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: Rq is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR5; X″ is NR4; O, S or S(O); A is a bond or —(CH2)m—(B)n—; B is C═O, NRg(C═O) or O(C═O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group —(CH2)p— wherein p is 2 to 4; and R1 to R6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

    摘要翻译: 本发明提供式(I)化合物; 或其盐或溶剂合物或N-氧化物; 其中:R q选自(a),(b)和(c)组; 星号表示与吡唑环的连接点; X是N或CR 5; X“是NR 4; O,S或S(O); A是键或 - (CH 2)m - (B)n - B为CO,NR(CO)或O(CO),其中R为氢或任选被羟基取代的C 1-4烷基烃基 或C 1-4烷氧基; m为0,1或2; n为0或1; 当存在时,R 0是氢或与NR a一起形成基团 - (CH 2 CH 2)n - - 其中p为2至4; 和R 1至R 6b如说明书中所定义。 式(I)化合物具有作为CDK抑制剂的活性,极光和GSK-3激酶可用于治疗或预防诸如由所述激酶介导的癌症的疾病。

    3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
    6.
    发明申请
    3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors 审中-公开
    3-(羰基)1h-吲唑化合物作为细胞周期蛋白依赖性激酶(cdk)抑制剂

    公开(公告)号:US20060135516A1

    公开(公告)日:2006-06-22

    申请号:US10524760

    申请日:2003-08-08

    CPC分类号: C07D513/04

    摘要: The invention provides a compound of the formula (I): wherein E is O, S, or NH; G is selected from hydrogen; carbocyclic and heterocyclic groups having from 3 to 12 ring members; and acyclic C1-8 hydrocarbyl groups optionally substituted; provided that E—G is not OH or SH and further provided that E—G does not contain the group O—O; two adjacent moieties selected from R3, R4, R5 and R6, together with the carbon atoms to which they are attached, form a fused heterocyclic group having from 5 to 7 ring members and 1, 2 or 3 ring heteroatoms selected from N, O and S; and the other two moieties selected from R3, R4, R5 and R6 are the same or different and are each as defined in the description. The Invention also provides compounds of the formula (I) for use as inhibitors of cyclin dependent kinases and for use in the treatment of disease states and conditions mediated by cyclin dependent kinases.

    摘要翻译: 本发明提供式(I)的化合物:其中E是O,S或NH; G选自氢; 具有3至12个环成员的碳环和杂环基; 和任选取代的非环状C 1-8烃基; 条件是E-G不是OH或SH,并且进一步规定E-G不含O-O基团; 选自R 3,R 4,R 5和R 6的两个相邻部分与碳原子一起 形成具有5至7个环成员和1,2或3个选自N,O和S的环杂原子的稠合杂环基; 并且选自R 3,R 4,R 5和R 6的另外两个部分是相同或 不同的并且各自如说明书中所定义。 本发明还提供用作细胞周期蛋白依赖性激酶抑制剂的式(I)化合物,并用于治疗由细胞周期蛋白依赖性激酶介导的疾病状态和状况。